link
Bookmarks
Myelin Oligodendrocyte Glycoprotein Autoantibody Myelitis
Jeffrey S. Ross, MD
To access 4,300 diagnoses written by the world's leading experts in radiology.Try it free - 15 days
0
0
0
0

KEY FACTS

  • Terminology

    • Imaging

      • Top Differential Diagnoses

        • Clinical Issues

          • Diagnostic Checklist

            TERMINOLOGY

            • Abbreviations

              • Myelin oligodendrocyte glycoprotein (MOG)
              • Longitudinally extensive transverse myelitis (LETM)
            • Synonyms

              • MOG-IgG-associated disorder (MOGAD)
            • Definitions

              • Inflammatory demyelinating disease distinct from multiple sclerosis (MS) and AQP4(+) neuromyelitis optica spectrum disorder (NMOSD)
              • Optic neuritis, transverse myelitis, AQP4-IgG seronegative inflammatory CNS demyelinating disorders with NMOSD-like phenotype; in children, acute disseminated encephalomyelitis (ADEM)

            IMAGING

            • General Features

              • MR Findings

                • Imaging Recommendations

                  DIFFERENTIAL DIAGNOSIS

                    CLINICAL ISSUES

                    • Presentation

                      • Demographics

                        • Natural History & Prognosis

                          • Treatment

                            DIAGNOSTIC CHECKLIST

                            • Consider

                              • Image Interpretation Pearls

                                Selected References

                                1. Chen JJ et al: Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 33(1):47-54, 2020
                                2. Cobo-Calvo A et al: Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. Curr Opin Neurol. 32(3):459-66, 2019
                                3. Dubey D et al: Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 76(3):301-9, 2019
                                4. Reindl M et al: Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 15(2):89-102, 2018
                                5. Ungureanu A et al: Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. Rev Neurol (Paris). 174(10):675-9, 2018
                                Related Anatomy
                                Loading...
                                Related Differential Diagnoses
                                Loading...
                                References
                                Tables

                                Tables

                                KEY FACTS

                                • Terminology

                                  • Imaging

                                    • Top Differential Diagnoses

                                      • Clinical Issues

                                        • Diagnostic Checklist

                                          TERMINOLOGY

                                          • Abbreviations

                                            • Myelin oligodendrocyte glycoprotein (MOG)
                                            • Longitudinally extensive transverse myelitis (LETM)
                                          • Synonyms

                                            • MOG-IgG-associated disorder (MOGAD)
                                          • Definitions

                                            • Inflammatory demyelinating disease distinct from multiple sclerosis (MS) and AQP4(+) neuromyelitis optica spectrum disorder (NMOSD)
                                            • Optic neuritis, transverse myelitis, AQP4-IgG seronegative inflammatory CNS demyelinating disorders with NMOSD-like phenotype; in children, acute disseminated encephalomyelitis (ADEM)

                                          IMAGING

                                          • General Features

                                            • MR Findings

                                              • Imaging Recommendations

                                                DIFFERENTIAL DIAGNOSIS

                                                  CLINICAL ISSUES

                                                  • Presentation

                                                    • Demographics

                                                      • Natural History & Prognosis

                                                        • Treatment

                                                          DIAGNOSTIC CHECKLIST

                                                          • Consider

                                                            • Image Interpretation Pearls

                                                              Selected References

                                                              1. Chen JJ et al: Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 33(1):47-54, 2020
                                                              2. Cobo-Calvo A et al: Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. Curr Opin Neurol. 32(3):459-66, 2019
                                                              3. Dubey D et al: Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 76(3):301-9, 2019
                                                              4. Reindl M et al: Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 15(2):89-102, 2018
                                                              5. Ungureanu A et al: Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. Rev Neurol (Paris). 174(10):675-9, 2018